Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...] …
Year: 2024
HHS and Congress should each take long-proposed actions—including a contentious action to curb certain Part B prescribing incentives—to better ensure [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A key argument in AstraZeneca’s lawsuit challenging Arkansas’ 340B contract pharmacy access law has already been rejected by a higher [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Novartis uses contradictory, “whiplash-inducing” arguments in its lawsuit challenging Mississippi’s 340B contract pharmacy law, hospital groups told a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Q: Where did you grow up?
I grew up in Addis Ababa, the capital city of Ethiopia.
Q: Where did you go to college/graduate school?
I completed my undergraduate studies at Addis Ababa University in Ethiopia and attended graduate school at St. John’s University in Queens, New York.
Q: What are your favorites?
Food: I mostly
…
SPONSORED CONTENT
TIP: To avoid unnecessary audit findings, it is critically important to review OPAIS data regularly.
HRSA audit
A long-anticipated bipartisan Senate bill to overhaul the 340B program appears on track for introduction before Congress enters recess at [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The health center advocacy group behind a proposed 340B program alternative recently slammed the 340B ACCESS Act, saying the newly [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Note: The Advanced 340B Operations Certificate Program is a separate Apexus offering that is not a part of the 340B Prime Vendor Program or otherwise associated with the Prime Vendor Agreement between HRSA and Apexus.
The 340B drug pricing
…